✨Exciting news #NephtSky The new #NephJC editorial interns are here! 📢Give them a follow and make them feel at home 👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇 www.nephjc.com/news/2025/6/...

NephJC Internship 2026-2027 — NephJC

Introducing NephJC’s brand new editorial internship class of 2026-2027

nephjc.com

“The kidneys make the stuff of philosophy itself.” ♥️ Thank you @msocomd.bsky.social

👉Before we start, a few reminders! Are you new to #NephJC ? Not sure what to do or how this works? Here is a quick rundown, an infographic made by Sinead Stoneman

⏰90 minutes left until #NephJC chat Hemoglobin targets have swung widely: 📈 Normalize Hb → CV harm signal 📉 Conservative targets → persistent symptoms Have we found the sweet spot yet?

⏰2 hours until #NephJC chat Anemia in CKD has shaped nephrology for decades ESAs, iron, transfusions, now HIF-PHIs But one question remains: 👉 Are we treating anemia optimally or cautiously?

#NephSky #MedSky 🩸Blood is thicker than water 🌊 Thankfully we thinned out the 2026 KDIGO Anemia Guidelines for you to peruse. Come discuss what's new. Tuesday 2/24/26 at 9pm EST on Bluesky! Summary by @jeyakumarmeyyappan.bsky.social www.nephjc.com/news/kdigo-anemia

2026 KDIGO Anemia Management Guidelines — NephJC

This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease

nephjc.com

Anemia research in CKD has had so much big fraud stories (which we don’t touch in the #NephJC write up) given the $$$ - the Normal Hct shady analysis from Amgen and PIs that @nejm.org allowed and still stays there - the Roxadustat p-hacking that brought down Fibrogen and tainted HIF-PHIs

Marc Soco, nephrologist from the Philippines and flozinator, looking forward to the discussion. No COI #NephJC

nice (and free) review of genetic testing and counselling in renal disease journals.lww.com/kidney360/fu... in @asnpublications.bsky.social #Kidney360 #NephSky #Genetics

In patients with CV disease, the “normal” range may be misleading Mortality is actually higher at K⁺ 3.5–4.0 mmol/L while high-normal levels (4.5–5.0) are associated with lower mortality 👀 #NephJC pubmed.ncbi.nlm.nih....

Hey everyone! Marc here, joining from the Philippines. No COI #NephJC

🍌🥑Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? 🎨 #Visualabstract by @jeyakumarmeyyappan.bsky.social ⏰ #NephJC chat on Jan 27, 9 pm EST www.nephjc.com/news/2026/1/...

¿Elevar el K⁺ al rango alto-normal puede reducir las descargas del DAI y las hospitalizaciones? 🎨Resumen visual por @jeyakumarmeyyappan.bsky.social ✍️Traducido por @dramiliflores.bsky.social www.nephjc.com/news/2026/1/...

Oh, the weather outside is frightful 🥶🥶 But #NephJC is so delightful, and since you've no place to go #NephSky... Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky Summary by @shelliefravel.bsky.social @salinesolut.bsky.social www.nephjc.com/news/potcast

POTCAST- K+ Pop and Arrhythmia Drop — NephJC

This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

nephjc.com

It's 2026!🎉 We will be counting down the Top Ten Nephrology Stories of 2025 on 1/6/26 at 9 pm EST. Join us on TWITTER (it will always be Twitter to us). Come on by #NephJC faithful for a lively discussion! You picked & we're count'em down. www.nephjc.com/news/2025/1/3/top-stories-in-nephrology-2025

Top Stories in Nephrology 2025 — NephJC

2025 was rich in successful stories. Here are the top 10 that impressed our audience.

nephjc.com

1/10 Last #NephJC we discussed dialysis frequency in AKI-D #TenPostNephJC We sought to answer an age-old question: Is less is really more? Or less is just simply what it is….less? pubmed.ncbi.nlm.nih.gov/41201895/

Have you ever “withheld” dialysis because the patient looked good despite questionable labs? Did you feel brave or nervous? 😅 We restrict fluids, potassium, phosphorus… But what about restricting dialysis itself? Let’s talk. #NephJC

Hi everyone ! Marc here from the Philippines 🇵🇭 sharing this “imprisonment” from Jerónimos Monastery in Lisbon 🇵🇹. From historic monasteries to modern trials, let’s LIBERATE-D our thinking. Looking forward to a great discussion! No COI. #NephJC

Gracias! @dramiliflores.bsky.social #NephSky LIBERATE-D: El Resumen Visual — #NephJC www.nephjc.com/news/2025/12/14/liberate-d-el-resumen-visual

LIBERATE-D: El Resumen Visual — NephJC

En pacientes con lesión renal aguda en diálisis, se evaluó si una estrategia más conservadora impacta en la recuperación renal. ¿Será que menos es más? Únete a la discusión del ensayo clínico LIBERATE...

nephjc.com

www.nephjc.com/news/... Check out the excellent #NephJC summary by @msocomd.bsky.social and @sejalplakhani.bsky.social

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D — NephJC

This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

nephjc.com

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial #NephSky This one might just change your mind 🧠🧠 Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social www.nephjc.com/news/liberated-aki

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D — NephJC

This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

nephjc.com

Holy Mackerel! 🐟 🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴‍☠️ #NephJC Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST Check out the PISCES VA by @brianrifkin.bsky.social www.nephjc.com/news/piscesva

PISCES: The Visual Abstract — NephJC

Curious how n-3 PUFAs may cut serious cardiovascular events in dialysis? 🐟 A big signal, a big dose, and a big discussion ahead — don’t miss this #NephJC! Check out the VA made by our master Brian...

nephjc.com

1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC Read the article 👇 www.nejm.org/doi/10....

T4d: That’s all partners 🤠 From here until the end of the year we will be catching up on all the late-breaking and simultaneous publications from #KidneyWk 2025. 😮‍💨 Ain’t no party like a #NephJC party!

T4c: #NephJC The rapid development of treatments for IgAN shows that nephrology can innovate like oncology and cardiology, to the benefit of our patients. Some final words of wisdom from #KidneyWk 2025

T4a: #NephJC We recently got to hear the patient voice from @jonathanpollack.bsk.social About his journey with IgAN and his excitement for a future of precision medicine while also calling for greater worldwide equity.

KDIGO IgA Guidelines: A Patient Voice — NephJC

We have a patient perspective on the new IgA Guidelines and what it means to live with IgA in these times.

nephjc.com

T3c: #NephJC The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.

#NephJC

Sorry will remain a dream for a while! We may have network meta-analysis - or will have to wait for them to go generic for an NIH (if NIH will even exist) or some other public funding body to do those trials #NephJC

Same here in 🇨🇦! Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market #NephJC

Physical Accessibility of Medicines in Countries Hosting Trials for FDA Approvals

This cross-sectional study aims to determine whether and when medicines receive market authorization in the countries where they are tested for US Food and Drug Administration approval, as well as tre...

jamanetwork.com